SHIONOGI & CO., LTD.

Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare

Osaka, Japan, September 13, 2013 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced today that ViiV Healthcare (Head Office: London; Chief Executive Officer: Dr. Dominique Limet) has disclosed data from the FLAMINGO study of the HIV integrase inhibitor, Tivicay® (dolutegravir).

The FLAMINGO study is a Phase IIIb/IV randomized open-label study comparing the safety and efficacy of Tivicay® to the protease inhibitor darunavir boosted by ritonavir (darunavir/r) in HIV-1 infected antiretroviral therapy-naïve subjects. The 48 week efficacy and safety data from FLAMINGO was presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013), Denver, CO, USA this week, and demonstrated superiority of Tivicay® to darunavir/r in spite of its non-inferiority study design.

Tivicay® is an integrase inhibitor for the treatment of patients with HIV, developed first by Shionogi-ViiV Healthcare LLC and then by ViiV Healthcare, following the new agreement between Shionogi and ViiV Healthcare announced in October, 2012. ViiV Healthcare filed New Drug Applications for Tivicay® in the US, EU and Canada on December 17, 2012. The US FDA approved Tivicay® on August 12, 2013 for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg.

Shionogi is very pleased that ViiV Healthcare is delivering innovative treatment options for people living with HIV worldwide, and, as a shareholder, will continue to work to maximize the value of Tivicay® and the other integrase inhibitor assets of ViiV Healthcare.

Forward-looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications
Shionogi & Co., Ltd.
Osaka Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Telephone: +81-3-3406-8164 Fax: +81-3-3406-8099